Compare Innovative Industrial Properties Inc (IIPR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs TG Therapeutics Inc — how do they compare? Innovative Industrial Properties Inc trades at $58.29 (market cap $1.67B), while TG Therapeutics Inc trades at $47.68 (market cap $7.58B). The key difference: TG Therapeutics Inc is far larger — about 4.5× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 13.17% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| IIPR | TGTX | |
|---|---|---|
Market Cap | $1.67B | $7.58B |
Sector | Real Estate | Health |
52-Week High | $64.67 | $59.06 |
52-Week Low | $44.58 | $26.94 |
Enterprise Value | $2.21B | $7.78B |
Dividend Yield | 13.17% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
